Dephosphorylation of endotoxin by alkaline phosphatase in vivo

K Poelstra, W W Bakker, P A Klok, J A Kamps, M J Hardonk, D K Meijer, K Poelstra, W W Bakker, P A Klok, J A Kamps, M J Hardonk, D K Meijer

Abstract

Natural substrates for alkaline phosphatase (AP) are at present not identified despite extensive investigations. Difficulties in imagining a possible physiological function involve its extremely high pH optimum for the usual exogenous substrates and its localization as an ecto-enzyme. As endotoxin is a substance that contains phosphate groups and is usually present in the extracellular space, we studied whether AP is able to dephosphorylate this bacterial product at physiological pH levels. We tested this in intestinal cryostat sections using histochemical methods with endotoxin from Escherichia coli and Salmonella minnesota R595 as substrate. Results show that dephosphorylation of both preparations occurs at pH 7.5 by AP activity. As phosphate residues in the lipid A moiety determine the toxicity of the molecule, we examined the effect of the AP inhibitor levamisole in vivo using a septicemia model in the rat. The results show that inhibition of endogenous AP by levamisole significantly reduces survival of rats intraperitoneally injected with E. coli bacteria, whereas this drug does not influence survival of rats receiving a sublethal dose of the gram-positive bacteria Staphylococcus aureus. In view of the endotoxin-dephosphorylating properties of AP demonstrated in vitro, we propose a crucial role for this enzyme in host defense. The effects of levamisole during gram-negative bacterial infections and the localization of AP as an ecto-enzyme in most organs as well as the induction of enzyme activity during inflammatory reactions and cholestasis is in accordance with such a protective role.

References

    1. Anal Biochem. 1976 May 7;72:407-12
    1. Nature. 1976 May 13;261(5556):136-7
    1. Lab Invest. 1981 Jul;45(1):38-45
    1. Am J Physiol. 1984 Apr;246(4 Pt 1):G393-400
    1. J Infect Dis. 1985 Jun;151(6):1012-8
    1. Hepatology. 1986 May-Jun;6(3):526-8
    1. Science. 1987 Sep 4;237(4819):1204-6
    1. J Histochem Cytochem. 1989 Mar;37(3):399-403
    1. Enzyme. 1988;40(4):217-22
    1. Hepatology. 1989 Nov;10(5):887-91
    1. Ann Intern Med. 1990 Aug 1;113(3):227-42
    1. J Cell Biol. 1991 May;113(4):743-56
    1. J Cell Biol. 1992 Feb;116(3):799-807
    1. Biochem Biophys Res Commun. 1992 Jan 15;182(1):269-75
    1. J Pediatr. 1992 Apr;120(4 Pt 1):510-5
    1. Eur Cytokine Netw. 1991 Nov-Dec;2(5):361-6
    1. Exp Hematol. 1992 May;20(4):388-90
    1. Arch Surg. 1992 Sep;127(9):1101-6
    1. Eur J Surg. 1992 Mar;158(3):157-64
    1. J Trauma. 1992 Oct;33(4):568-73
    1. Arch Surg. 1993 Feb;128(2):200-4; discussion 204-5
    1. J Hepatol. 1993 Apr;18(1):85-95
    1. Acta Histochem. 1993 Feb;94(1):89-96
    1. Infect Immun. 1994 Jan;62(1):119-25
    1. Eur J Biochem. 1993 Dec 1;218(2):555-63
    1. Clin Infect Dis. 1993 Nov;17 Suppl 2:S515-9
    1. FASEB J. 1994 Feb;8(2):217-25
    1. Hepatology. 1994 Apr;19(4):1013-22
    1. Clin Chem. 1994 May;40(5):803-10
    1. Int J Biochem. 1994 Feb;26(2):273-7
    1. Eur J Biochem. 1994 May 15;222(1):183-94
    1. Infect Immun. 1994 Jul;62(7):2715-21
    1. Kidney Int. 1994 Apr;45(4):1120-31
    1. Int J Clin Lab Res. 1994;24(2):61-79
    1. J Biomed Mater Res. 1994 Nov;28(11):1295-301
    1. Infect Immun. 1995 May;63(5):1835-9
    1. J Immunol. 1995 Aug 15;155(4):2085-95
    1. Methods Enzymol. 1995;250:582-614
    1. Pharm Biotechnol. 1995;6:495-524
    1. J Exp Med. 1995 Dec 1;182(6):1673-82
    1. Br J Haematol. 1995 Dec;91(4):838-45
    1. J Inflamm. 1996;46(2):98-105
    1. Drugs. 1996;52 Suppl 2:9-17
    1. J Lab Clin Med. 1996 Dec;128(6):594-600
    1. Lab Invest. 1997 Mar;76(3):319-27
    1. Am J Clin Pathol. 1957 Jan;27(1):13-23
    1. Proc Natl Acad Sci U S A. 1980 May;77(5):2857-60

Source: PubMed

3
Iratkozz fel